Dexcom Inc. ($DXCM) reported preliminary fourth-quarter 2024 revenue of $1.113 billion, reflecting an 8% year-over-year increase and aligning with consensus estimates of $1.1 billion. For the full year 2024, the company achieved revenue of $4.032 billion, marking an 11% increase compared to the previous year and meeting consensus expectations. The company also updated its gross margin guidance for 2024 to 62%, citing non-cash charges related to damaged inventory and production issues. Looking ahead, Dexcom anticipates a 14% revenue growth for 2025 and expects to generate $1.4 billion in adjusted EBITDA. Additionally, the company noted that two of the three largest pharmacy benefit managers will now cover continuous glucose monitoring (CGM), potentially increasing access to 5 million additional patients with type 2 diabetes. In related news, Dallas-based company $DAL expects to generate over $4 billion in free cash flow in 2025, which will support debt reduction and lower its leverage ratio to two times or less.